A practical guide to recognize allergic and immunologic skin diseases: diagnosis at first sight

Abstract

Allergic and immunologic skin diseases are becoming increasingly common and this requires clinicians to be able to recognize and diagnose them. A joint meeting (GET TOGETHER 2022) of the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC) and the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA) aimed to review the current knowledge on the differential diagnosis of contact dermatitis, atopic dermatitis, hereditary angioedema, urticaria, and cutaneous mastocytosis. The most important aspects to take into consideration when faced with a new cutaneous manifestation are the clinical features of the lesions, their distribution, age of onset, and comorbidities/aggravating factors. The document does not aim to provide an exhaustive and comprehensive description of all allergic and immunologic skin diseases. Instead, it should be a reference tool for the clinician who is faced with the onset of a new skin manifestation and its differential diagnosis.

Keywords

Differential diagnosis / skin / contact dermatitis / atopic dermatitis / hereditary angioedema / urticaria / cutaneous mastocytosis / allergy

References

[1] Gravitz L. Skin. Nature. 2018; 563: S83.

[2] Bains SN, Nash P, Fonacier L. Irritant Contact Dermatitis. Clin Rev Allergy Immunol. 2019; 56: 99-109.

[3] Adler BL, DeLeo VA. Allergic Contact Dermatitis. JAMA Dermatol. 2021; 157: 364.

[4] Deleuran M, Vestergaard C. Clinical heterogeneity and differential diagnosis of atopic dermatitis. Br J Dermatol. 2014; 170: 2-6.

[5] So JK, Hamstra A, Calame A, Hamann CR, Jacob SE. Another Great Imitator: Allergic Contact Dermatitis Differential Diagnosis, Clues to Diagnosis, Histopathology, and Treatment. Curr Treat Options Allergy. 2015; 2: 333-48.

[6] Pongpairoj K, Puangpet P, Thaiwat S, McFadden JP. Diagnosing Allergic Contact Dermatitis Through Elimination, Perception, Detection and Deduction. Am J Clin Dermatol. 2017; 18: 651-61.

[7] Milam EC, Jacob SE, Cohen DE. Contact Dermatitis in the Patient with Atopic Dermatitis. J Allergy Clin Immunol Pract. 2019; 7: 18-26.

[8] Schmidlin K, Sani S, Bernstein DI, Fonacier L. A Hands-on Approach to Contact Dermatitis and Patch Testing. J Allergy Clin Immunol Pract. 2020; 8: 1883-93.

[9] Yüksel YT, Nørreslet LB, Thyssen JP. Allergic Contact Dermatitis in Patients with Atopic Dermatitis. Curr Derm Rep. 2021; 10: 67-76.

[10] Kovitwanichkanont T, Chong AH. Superficial fungal infections. Aust J Gen Pract. 2019; 48: 706-11.

[11] Chamorro MJ, Syed HA, House SA. Tinea Manuum. Treasure Island (FL): StatPearls Publishing; 2024.

[12] Errichetti E, Stinco G. Dermoscopy in tinea manuum. An Bras Dermatol. 2018; 93: 447-8.

[13] Telner P, Fekete Z. The capillary responses in psoriatic skin. J Invest Dermatol. 1961; 36: 225-30.

[14] Pinkus H, Mehregan AH. The primary histologic lesion of seborrheic dermatitis and psoriasis. J Invest Dermatol. 1966; 46: 109-16.

[15] Schubert C, Christophers E. Mast cells and macrophages in early relapsing psoriasis. Arch Dermatol Res. 1985; 277: 352-8.

[16] Kolesnik M, Franke I, Lux A, Quist SR, Gollnick HP. Eczema in Psoriatico: An Important Differential Diagnosis Between Chronic Allergic Contact Dermatitis and Psoriasis in Palmoplantar Localization. Acta Derm Venereol. 2018; 98: 50-8.

[17] Al-Mutairi N, Abdalla TO, Nour TM. Resistant palmoplantar lesions in patients of psoriasis: evaluation of the causes and comparison of the frequency of delayed-type hypersensitivity in patients without palm and sole lesions. Med Princ Pract. 2014; 23: 561-7.

[18] Bangsgaard N, Engkilde K, Thyssen JP, Linneberg A, Nielsen NH, Menné T, et al. Inverse relationship between contact allergy and psoriasis: results from a patient- and a population-based study. Br J Dermatol. 2009; 161: 1119-23.

[19] Caca-Biljanovska N, V’lckova-Laskoska M, Balabanova-Stefanova M, Grivceva-Panovska V. Frequency of delayed-type hypersensitivity to contact allergens in palmo-plantar psoriasis. Prilozi. 2005; 26: 131-41.

[20] Malhotra V, Kaur I, Saraswat A, Kumar B. Frequency of patch-test positivity in patients with psoriasis: a prospective controlled study. Acta Derm Venereol. 2002; 82: 432-5.

[21] Quaranta M, Eyerich S, Knapp B, Nasorri F, Scarponi C, Mattii M, et al. Allergic contact dermatitis in psoriasis patients: typical, delayed, and non-interacting. PLoS One. 2014; 9: e101814.

[22] Naldi L, Rebora A. Seborrheic dermatitis. N Engl J Med. 2009; 360: 387-96.

[23] Dessinioti C, Katsambas A. Seborrheic dermatitis: etiology, risk factors, and treatments: facts and controversies. Clin Dermatol. 2013; 31: 343-51.

[24] Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al., editors. Fitzpatrick’s dermatology. 9th ed. McGraw-Hill Education; 2019.

[25] Cohen B. Differential Diagnosis of Diaper Dermatitis. Clin Pediatr (Phila). 2017; 56: 16S-22S.

[26] Lofgren SM, Warshaw EM. Dyshidrosis: epidemiology, clinical characteristics, and therapy. Dermatitis. 2006; 17: 165-81.

[27] Calle Sarmiento PM, Chango Azanza JJ. Dyshidrotic Eczema: A Common Cause of Palmar Dermatitis. Cureus. 2020; 12: e10839.

[28] Angelini G, Vena GA. Manuale di dermatologia. Sociatá Editrice Universo; 1985.

[29] Gangar J, Thiagarajan K, Veeraraghavan N. Pruritic Rash on the Hands and Feet. Am Fam Physician. 2018; 98: 685-6.

[30] Murphy PB, Atwater AR, Mueller M. Allergic Contact Dermatitis. Treasure Island (FL): StatPearls Publishing; 2024.

[31] Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020; 396: 345-60.

[32] Ständer S. Atopic Dermatitis. N Engl J Med. 2021; 384: 1136-43.

[33] Barrett M, Luu M. Differential Diagnosis of Atopic Dermatitis. Immunol Allergy Clin North Am. 2017; 37: 11-34.

[34] Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021; 397: 1301-15.

[35] Ji C, Wang H, Bao C, Zhang L, Ruan S, Zhang J, et al. Challenge of Nail Psoriasis: An Update Review. Clin Rev Allergy Immunol. 2021; 61: 377-402.

[36] Engelman D, Yoshizumi J, Hay RJ, Osti M, Micali G, Norton S, et al. The 2020 International Alliance for the Control of Scabies Consensus Criteria for the Diagnosis of Scabies. Br J Dermatol. 2020; 183: 808-20.

[37] Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019; 133: 1703-14.

[38] Krol A, Krafchik B. The differential diagnosis of atopic dermatitis in childhood. Dermatol Ther. 2006; 19: 73-82.

[39] Cerroni L. Skin Lymphoma: The Illustrated Guide. 5th ed. John Wiley & Sons; 2020.

[40] Silverberg JI. Adult-Onset Atopic Dermatitis. J Allergy Clin Immunol Pract. 2019; 7: 28-33.

[41] Saulite I, Hoetzenecker W, Weidinger S, Cozzio A, Guenova E, Wehkamp U. Sézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and Targets. Biomed Res Int. 2016; 2016: 9717530.

[42] Sidiropoulou P, Nikolaou V, Marinos L, Voudouri D, Komini E, Economidi A, et al. The different faces of mycosis fungoides: results of a single-center study. Int J Dermatol. 2020; 59: 314-20.

[43] Willemze R. Mycosis fungoides variants-clinicopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018; 37: 11-7.

[44] Zackheim HS, McCalmont TH. Mycosis fungoides: the great imitator. J Am Acad Dermatol. 2002; 47: 914-8.

[45] Nashan D, Faulhaber D, Ständer S, Luger TA, Stadler R. Mycosis fungoides: a dermatological masquerader. Br J Dermatol. 2007; 156: 1-10.

[46] Miyagaki T, Sugaya M. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis. J Dermatol Sci. 2011; 64: 1-6.

[47] Mistry N, Gupta A, Alavi A, Sibbald RG. A review of the diagnosis and management of erythroderma (generalized red skin). Adv Skin Wound Care. 2015; 28: 228-36.

[48] O’Connell KA, LaChance AH. Dermatomyositis. N Engl J Med. 2021; 384: 2437.

[49] Bailey EE, Fiorentino DF. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep. 2014; 16: 465.

[50] Horiuchi T. Hereditary Angioedema from 1888 to 2018 -Progress and Problems. Intern Med. 2018; 57: 3065-6.

[51] Bork K, Wulff K, Witzke G, Hardt J. Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations . Allergy. 2015; 70: 1004-12.

[52] Busse PJ, Christiansen SC. Hereditary Angioedema. N Engl J Med. 2020; 382: 1136-48.

[53] Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012; 130: 692-7.

[54] Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Aygören-Pürsün E, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. Allergy. 2022; 77: 1961-90.

[55] Rubinstein E, Stolz LE, Sheffer AL, Stevens C, Bousvaros A. Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency. BMC Gastroenterol. 2014; 14: 71.

[56] Jalaj S, Scolapio JS. Gastrointestinal manifestations, diagnosis, and management of hereditary angioedema. J Clin Gastroenterol. 2013; 47: 817-23.

[57] Obtułowicz P, Stobiecki M, Dyga W, Juchacz A, Popiela T, Obtułowicz K. Abdominal and pelvic imaging in the diagnosis of acute abdominal attacks in patients with hereditary angioedema due to C1-inhibitor deficiency. Postepy Dermatol Alergol. 2022; 39: 749-56.

[58] Bova M, De Feo G, Parente R, De Pasquale T, Gravante C, Pucci S, et al. Hereditary and Acquired Angioedema: Heterogeneity of Pathogenesis and Clinical Phenotypes. Int Arch Allergy Immunol. 2018; 175: 126-35.

[59] Manning ME. Hereditary angioedema: Differential diagnosis, diagnostic tests, and family screening. Allergy Asthma Proc. 2020; 41: S22-5.

[60] Inomata N. Recent advances in drug-induced angioedema. Allergol Int. 2012; 61: 545-57.

[61] Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev. 1998; 50: 357-86.

[62] Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE Inhibitor-Induced Angioedema: a Review. Curr Hypertens Rep. 2018; 20: 55.

[63] Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008; 51: 1624-30.

[64] Abdi R, Dong VM, Lee CJ, Ntoso KA. Angiotensin II receptor blocker-associated angioedema: on the heels of ACE inhibitor angioedema. Pharmacotherapy. 2002; 22: 1173-5.

[65] Mansi M, Zanichelli A, Coerezza A, Suffritti C, Wu MA, Vacchini R, et al. Presentation, diagnosis and treatment of angioedema without wheals: a retrospective analysis of a cohort of 1058 patients. J Intern Med. 2015; 277: 585-93.

[66] Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. ; HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014; 69: 602-16.

[67] Gülbahar O. Angioedema without wheals: a clinical update. Balkan Med J. 2021; 38: 73-81.

[68] Faisant C, Boccon-Gibod I, Mansard C, Dumestre Perard C, Pralong P, Chatain C, et al. Idiopathic histaminergic angioedema without wheals: a case series of 31 patients. Clin Exp Immunol. 2016; 185: 81-5.

[69] Wu MA, Perego F, Zanichelli A, Cicardi M. Angioedema Phenotypes: Disease Expression and Classification. Clin Rev Allergy Immunol. 2016; 51: 162-9.

[70] Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. ; Endorsed by the following societies: AAAAI, AAD, AAIITO, ACAAI, AEDV, APAAACI, ASBAI, ASCIA, BAD, BSACI, CDA, CMICA, CSACI, DDG, DDS, DGAKI, DSA, DST, EAACI, EIAS, EDF, EMBRN, ESCD, GA²LEN, IAACI, IADVL, JDA, NVvA, MSAI, ÖGDV, PSA, RAACI, SBD, SFD, SGAI, SGDV, SIAAIC, SIDeMaST, SPDV, TSD, UNBB, UNEV and WAO. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria . Allergy. 2018; 73: 1393-414.

[71] He L, Yi W, Huang X, Long H, Lu Q. Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management. Clin Rev Allergy Immunol. 2021; 61: 424-48.

[72] Kossard S, Hamann I, Wilkinson B. Defining urticarial dermatitis: a subset of dermal hypersensitivity reaction pattern. Arch Dermatol. 2006; 142: 29-34.

[73] Byth LA. Urticarial dermatitis: a nosological dilemma. Int J Dermatol. 2019; 58: e196-8.

[74] Hannon GR, Wetter DA, Gibson LE. Urticarial dermatitis: clinical features, diagnostic evaluation, and etiologic associations in a series of 146 patients at Mayo Clinic (2006-2012). J Am Acad Dermatol. 2014; 70: 263-8.

[75] Kim TI, Park HJ, Won YY, Choi H, Jeong KH, Sung JY, et al. Basement Membrane Status Is Intact in Urticarial Dermatitis vs. Adult-Onset Atopic Dermatitis. Ann Dermatol. 2018; 30: 258-61.

[76] Ben Kridis W, Khanfir A. An uncommon case of pancreatic adenocarcinoma revealed by dermatitis. JGH Open. 2022; 6: 280-1.

[77] Banan P, Butler G, Wu J. Retrospective chart review in a cohort of patients with urticarial dermatitis. Australas J Dermatol. 2014; 55: 137-9.

[78] Radhakrishnan RC, Basu G, George RE, Parmar H, Tamilarasi V. Rituximab-induced urticarial dermatitis during the treatment of membranous nephropathy. Saudi J Kidney Dis Transpl. 2017; 28: 657-60.

[79] Ikediobi O, Eichenfield DZ, Barrio VR. Eosinophilic cellulitis in response to BNT162b2 COVID-19 vaccination. Pediatr Dermatol. 2022; 39: 823-4.

[80] Mata DA, Lian JW, Krakowski A, Agarwala S, Hafeez F. Histopathologic and immunophenotypic features of idiopathic dermal hypersensitivity reaction/urticarial dermatitis: A clinicopathologic study. J Cutan Pathol. 2021; 48: 592-5.

[81] Nguyen CN, Kim SJ. Dermatitis Herpetiformis: An Update on Diagnosis, Disease Monitoring, and Management. Medicina (Kaunas). 2021; 57: 843.

[82] Reunala T, Salmi TT, Hervonen K, Kaukinen K, Collin P. Dermatitis Herpetiformis: A Common Extraintestinal Manifestation of Coeliac Disease. Nutrients. 2018; 10: 602.

[83] Antiga E, Maglie R, Quintarelli L, Verdelli A, Bonciani D, Bonciolini V, et al. Dermatitis Herpetiformis: Novel Perspectives. Front Immunol. 2019; 10: 1290.

[84] Ohshima Y, Tamada Y, Matsumoto Y, Hashimoto T. Dermatitis herpetiformis Duhring with palmoplantar keratosis. Br J Dermatol. 2003; 149: 1300-2.

[85] Holtmeier W, Pfänder M, Zollner TM, Kaufmann R, Caspary WF. Distinct TCR δ repertoires are present in the cutaneous lesions and inflamed duodenum of patients with dermatitis herpetiformis. Exp Dermatol. 2002; 11: 527-31.

[86] Zone JJ, Meyer LJ, Petersen MJ. Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis. Arch Dermatol. 1996; 132: 912-8.

[87] Görög A, Antiga E, Caproni M, Cianchini G, De D, Dmochowski M, et al. S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2021; 35: 1251-77.

[88] Borroni G, Biagi F, Ciocca O, Vassallo C, Carugno A, Cananzi R, et al. IgA anti-epidermal transglutaminase autoantibodies: a sensible and sensitive marker for diagnosis of dermatitis herpetiformis in adult patients. J Eur Acad Dermatol Venereol. 2013; 27: 836-41.

[89] Parker SR, MacKelfresh J. Autoimmune blistering diseases in the elderly. Clin Dermatol. 2011; 29: 69-79.

[90] Moro F, Fania L, Sinagra JLM, Salemme A, Di Zenzo G. Bullous Pemphigoid: Trigger and Predisposing Factors. Biomolecules. 2020; 10: 1432.

[91] Schmidt E, Goebeler M, Hertl M, Sárdy M, Sitaru C, Eming R, et al. S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges. 2015; 13: 713-27.

[92] Genovese G, Di Zenzo G, Cozzani E, Berti E, Cugno M, Marzano AV. New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update. Front Immunol. 2019; 10: 1506.

[93] Ruggiero A, Megna M, Villani A, Comune R, Fabbrocini G, di Vico F. Strategies to Improve Outcomes of Bullous Pemphigoid: A Comprehensive Review of Clinical Presentations, Diagnosis, and Patients’ Assessment. Clin Cosmet Investig Dermatol. 2022; 15: 661-73.

[94] Hamad A, Jithpratuck W, Krishnaswamy G. Urticarial vasculitis and associated disorders. Ann Allergy Asthma Immunol. 2017; 118: 394-8.

[95] Jachiet M, Flageul B, Deroux A, Le Quellec A, Maurier F, Cordoliani F, et al. ; French Vasculitis Study Group. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol. 2015; 67: 527-34.

[96] Kolkhir P, Grakhova M, Bonnekoh H, Krause K, Maurer M. Treatment of urticarial vasculitis: A systematic review. J Allergy Clin Immunol. 2019; 143: 458-66.

[97] Kamyab K, Ghodsi SZ, Ghanadan A, Taghizadeh J, Karimi S, Nasimi M. Eosinophilic infiltration: an under-reported histological finding in urticarial vasculitis. Int J Dermatol. 2019; 58: 825-9.

[98] Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127: 2391-405.

[99] Pardanani A. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management. Am J Hematol. 2021; 96: 508-25.

[100] Di Raimondo C, Del Duca E, Silvaggio D, Di Prete M, Lombardo P, Mazzeo M, et al. Cutaneous mastocytosis: A dermatological perspective. Australas J Dermatol. 2021; 62: e1-7.

[101] Valent P, Escribano L, Broesby-Olsen S, Hartmann K, Grattan C, Brockow K, et al. ; European Competence Network on Mastocytosis. Proposed diagnostic algorithm for patients with suspected mastocytosis: a proposal of the European Competence Network on Mastocytosis. Allergy. 2014; 69: 1267-74.

[102] Lyons JJ, Yu X, Hughes JD, Le QT, Jamil A, Bai Y, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number . Nat Genet. 2016; 48: 1564-9.

[103] Luskin KT, White AA, Lyons JJ. The Genetic Basis and Clinical Impact of Hereditary Alpha-Tryptasemia. J Allergy Clin Immunol Pract. 2021; 9: 2235-42.

[104] Sprinzl B, Greiner G, Uyanik G, Arock M, Haferlach T, Sperr WR, et al. Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond. Int J Mol Sci. 2021; 22: 2458.

[105] Lyons JJ. Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features. Immunol Allergy Clin North Am. 2018; 38: 483-95.

[106] Robey RC, Wilcock A, Bonin H, Beaman G, Myers B, Grattan C, et al. Hereditary Alpha-Tryptasemia: UK Prevalence and Variability in Disease Expression. J Allergy Clin Immunol Pract. 2020; 8: 3549-56.

[107] Lyons JJ, Sun G, Stone KD, Nelson C, Wisch L, O’Brien M, et al. Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. J Allergy Clin Immunol. 2014; 133: 1471-4.

[108] Greiner G, Sprinzl B, Górska A, Ratzinger F, Gurbisz M, Witzeneder N, et al. Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis. Blood. 2021; 137: 238-47.

[109] Glover SC, Carter MC, Korošec P, Bonadonna P, Schwartz LB, Milner JD, et al. Clinical relevance of inherited genetic differences in human tryptases: Hereditary alpha-tryptasemia and beyond. Ann Allergy Asthma Immunol. 2021; 127: 638-47.